Welcome to HOT TOPIC, Evmedreview’s latest special feature of compelling, in-depth articles from major voices in the field of evolutionary medicine, highlighting urgent problems in the world of medicine today that evolutionary medicine has either identified, or upon which it is shedding some new light, and where it may be able to contribute to solutions. This inaugural article is written by Prof. Martin J. Blaser, of the New York University School of Medicine. We have known for some time that overuse of antibiotics can lead to multiple antibiotic resistance. But Blaser here draws our attention to, and describes in fine detail, the way in which over-prescription of antibiotics is gradually depleting human microbiomes and may be seeding a generation-by-generation growth of a wide spectrum of life-shortening diseases in our children. Scroll to the end to see the interesting comments  and add your own now, or send us a potential post at [email protected].

The long-term risks of antibiotic treatment in childhood: Antibiotics as panacea, or as opening Pandora’s box?

Martin J. Blaser

By Martin Blaser, M.D.

Muriel G. and George W. Singer Professor of Translational Medicine
Director, Human Microbiome Program
New York University Langone Medical Center
New York, NY 10016

Magic Bullets.

The development of antibiotics was one of the greatest discoveries of the 20th century, and arguably the most important in the field of medicine and health (1). Not only can antibiotics be used to treat diseases that were previously untreatable, but they provide the safety net without which surgery, chemotherapy for cancer, and transplantation would have markedly heightened risk or be impossible.

In consequence, essentially since their widespread introduction in the years following World War II, the notion that antibiotics are miraculous has been a part of the general idiom, to both health professionals and the public alike. Thus, not surprisingly, antibiotics have been used more and more, for all manner of purposes—in the clinic, on the farm, in the aquarium. Their direct use in people worldwide was estimated at more than 70 billion doses annually (2), or 10 doses for every man, woman, and child on Earth. In the United States, about 262 million courses were used in 2011, a rate of 842/1000 population (3), more than five courses for every six people. For young children, rates are even higher, estimated as 1.35/year for US children in the first 2 years of life, representing nearly 3 courses during that time, and about 10 courses by the age of 10 (4).

This enormous use has been predicated on a conceptual framework of few or no substantial risks to the individual from taking antibiotics. As such, any perceived benefit, however small, is considered an indication for antibiotic use. Thus, to both physicians and patients, why not try an antibiotic? “Can’t hurt and it might help!”

2. Bacteria, our ancient companions, as our partners.

Bacteria were here first on this planet, evolving about 4 billion years ago. All known forms of life evolved from bacteria. Further, all of this subsequent life evolved in the presence of bacteria. Thus, the very existence of all plants and animals on earth is based on their ability to control or harness adjacent bacteria, whether in or on them or nearby.

All animal species have their own unique residential microorganisms. These organisms, which we refer to as the microbiota, live in and on their host, and when the intersecting metabolic pathways of microbes and host are included, the constellation has been referred to as the microbiome. In large hosts like humans, each of the multiple physiologic niches includes its own microbiome.

In animals, there is an important vertical component to the inheritance of each host’s microbiome. Stated differently, in addition to our human genome that we inherit from our parents, each of us inherits much of our microbiome from our mother. Recent studies of primates show strong co-speciation of hosts and microbes, representing a span of about 15 million years of hominid evolution (5, 6). This is consistent with studies more broadly across mammals, illustrating similar conservation over even longer time spans (7).

Thus, the genes we inherit from mom are not just human genes, but they are microbial. Viewed in this way, our microbiome represents a portion of our individual genetic endowment, as well as a component of our gene pool (8). The tension between vertical (8) and horizontal transmission of our microbiome is important, but most current data suggest that among long-term microbial residents, vertical predominates (9).

One further point is that even though babies inherit much of their vast microbiota from mom, the initial community structure is quite different from that of adults. However, by the age of 3 years, it becomes much more adult-like in its structure (10). Thus, the first three years of life are when the predominantly vertically acquired microbiome is developing its adult form. It is also the time when babies are developing their immunity, metabolism, and cognition.

As such, the first three years of life are a most critical time for human development. One hypothesis is that the development of a normally maturing microbiome affects physiological processes in salutary ways. We can conceive of a situation in which the initial microbiota may provide contextual instructions to the immune system to distinguish between self and non-self, adding the nuances of grey to a black/white dichotomy. Similarly, the infant must lay down the appropriate amount of adipose tissue, appropriate to its nutritional milieu, that will optimize the relationship between energy utilization and storage that will be a determinant of reproductive success. For example, if a young individual builds greater capacity for energy storage, it can better survive famines, but if it puts more into muscle and bone, it can fight and hunt better; this is a classical trade-off. Similarly, in social animals, the brain of the growing infant must set a cognitive pathway about how open or closed to interpersonal signaling they will be as they mature. There is widening evidence that the early life microbiome is a participant in the dialogue that determines how the host makes these immunologic, metabolic, and cognitive decisions. But the developing microbiome, crucial in the early life window of development, has limited resilience, and is vulnerable to perturbation (8, 11).

3. How antibiotics affect our bacterial partnerships.

We can especially focus on antibiotics as key agents causing micro-ecological change, because their use is so pervasive. Antibiotics were generally designed and used to eliminate single pathogens causing infections; doses were selected to achieve blood levels that inhibit the pathogen’s replication. However, there was little or no consideration of their effects when applied to the diverse microbiota colonizing each host. Such interactions were considered to be off-target, and in the short-term were generally mild, causing GI tract upset, skin rashes, or overgrowth by yeasts, for example. Usually there were no clinical effects at all. It was this apparent safety that lulled professionals and lay-people alike into what we have called ‘antibiotic sleep’ (12).

Yet the question remained, could off-target effects have long-term consequences?

Paradoxically, the answer came 70 years ago, near the beginning of the antibiotic era with strong evidence, and yet until recently it was missed (13, 14). The answers came from the practices of farmers who recognized that feeding antibiotics (generally in low doses for prolonged time periods) to their livestock promoted their growth (15). These widespread and extensively validated effects indicate that exposure to antibiotics changed the development of the recipients. It was a profound point, but the larger implications for human health were missed.

Collectively, the farmers made four crucial observations:

  1. Antibiotics worked in cows, swine, fish, chickens, and turkeys, among other species. This is a wide swath of vertebrate evolution. That it was not host species-specific indicated that the antibiotic exposure affected a broad and common principle.
  1. Virtually any anti-bacterial agent was effective, regardless of chemical composition, class, structure, or spectrum, but anti-virals and anti-fungals had no effects. The same anti-bacterial agents worked across multiple animal species, indicating that it was their anti-bacterial effects, not any specific activities of each compound that were the key to their effectiveness.
  1. Importantly, the younger the animals were when the antibiotics were started, the greater the effects—on growth rate, and on feed efficiency—the ability to convert food calories into body mass, which after all is what farmers are trying to do. This indicates that the process affected is developmental. Conversely, the later in life it was started in the animals, the lower the effect. This observation provides evidence that there may be a crucial ‘window’, the period of time during which an animal is susceptible to the antibiotic effects.
  1. Agents given orally were more effective for growth promotion than those given parenterally.
  1. Long-term health risks from perturbing our bacterial partnerships during childhood.

Taken together, these observations point to the importance of the bacteria of the gastrointestinal tract, across animal species, early in life, as the principal targets of the antibiotics, and as the principal intermediates to explain the efficacy of growth promotion. My laboratory has conducted studies in experimental animals that indicate that antibiotic use perturbs the intestinal microbiota and that it is the altered microbiota that is both necessary and sufficient to confer the effects on growth and metabolism (16-19). Parallel studies in other mouse models indicate activities that affect immunological development and disease (20).

In total, these observations are consistent with a role for antibiotics in the rise of many diseases that have their origins in childhood that are affected by altered immunological, metabolic, or cognitive processes. These include (but are not limited to) disorders that are primarily metabolic (obesity and type-2 diabetes), immunologic (asthma, allergies, juvenile (type-1) diabetes, inflammatory bowel disease), and cognition (autism and attention deficit disorder). These in fact are many of the diseases that have increased in incidence or have become epidemic around the world in recent decades.

With this theoretical and experimental background, a growing body of epidemiologic studies of human children have addressed the question of whether in fact antibiotic exposures are associated with the later development of these diseases. In brief, although the many studies differ in the diseases studied, their size, locales, definitions used, study designs, and statistical tools, there is substantial consistency showing positive associations (21-33).

Based on the totality of the evidence, I believe that we will find that every dose of an antibiotic given to young children has a delayed cost. For example, there might be an x% cost of asthma, y% cost of juvenile diabetes, and z% cost of inflammatory bowel disease. Each exposure might confer multiple costs, and my theory is that the costs are cumulative across exposures. However, we do not yet know what is the critical age window, nor the amounts for x, y, and z. Yet data are beginning to clarify the picture. A recent large study, involving all Danish children born over a nine-year period, showed that each antibiotic course was associated with an 18% increase in the risk of childhood-onset Crohn’s disease compared to untreated controls (23). In several epidemiological studies, the highest risks for later illnesses were associated with exposures in the first six months of life (26, 27), which is not surprising.

It is likely that the exact costs will vary in different populations, reflecting the nature of the status quo ante microbiome, which varies across populations (10, 34, 35), effects of maternal pre-partum antibiotics (36, 37), the extent of Cesarean delivery (21-25), the specific antibiotics used (38), and the particular disease risk of highest concern. Further, variations in health outcome may also occur because a perturbed microbiome is not the only factor driving to disease.

  1. Damage down the generations, and solutions.

Finally, and perhaps most worrisome is that antibiotics given in one generation might affect the health in the next and future generations. We already know that certain medicines given during pregnancy can adversely affect the health of the next generation. There is growing evidence of associations of maternal antibiotic use with particular outcomes (36, 37, 39, 40). However, this must be clearly sorted out since any observed associations might reflect the underlying infections for which the antibiotics were given. Yet, antibiotic use during pregnancy and even before (36, 37) will impact the maternal microbiome, just before the hand-off to the next generation. The girls of today are the mothers of tomorrow, and antibiotic exposures have the potential to affect their microbial compositions in permanent ways. It is important to reiterate that antibiotics are not the only factor that could affect the early life microbiota development and transfer to the next generation. Others include a variety of modern foods and food additives (e.g. emulsifiers, artificial sweeteners) (41, 42), and practices related to pregnancy and delivery (e.g. prophylaxes, Cesarean section, antibacterial washes).

We have hypothesized that the changes in microbiome are cumulative across recent human generations, reflecting a stepping down in biodiversity (14). If this is correct, and evidence is accumulating that it is (10, 34, 43-45), then we must halt the decline, and reverse it through restorative steps (35). I predict that the health practices of the future will involve restoring particular “missing microbes” to young children, based on the microbial needs of all children, and the needs of that specific child (46, 47).

In any event, the doctors of the future will need to take into consideration antibiotic cost data vis a vis the potential benefits in making therapeutic decisions. There are many infections that must be treated, but also a large number for which the benefit is marginal or nil. As in so many other areas of medicine, doctors will need to calculate potential benefit versus potential risk in the patient sitting in front of them, considering the future as well. As our knowledge of the costs becomes more precise, this will become increasingly necessary.

We must alter our views of the “antibiotic umbrella”, under which most of medicine is conducted. Doctors will have to improve their clinical skills to minimize antibiotic exposures unless necessary. There already is enormous heterogeneity in prescribing practices (3, 48-50), so some doctors already are there, while others lag substantially. In Sweden, per capita antibiotic use is about 40% of that in the USA (51), so change is not impossible. But change we must.

Acknowledgments. Supported by R01DK090989 and U01AI22285 from the National Institutes of health, and by the Ziff Family, Knapp, and the C & D funds. I thank Tiffany Archuleta and Joyce Ying for bibliographic support.


  1. M. Burnet, in Natural History of Infectious Disease. (Cambridge University Press, New York, 1953).
  2. T. P. Van Boeckel et al., Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. The Lancet. Infectious diseases 14, 742 (Aug, 2014).
  3. L. A. Hicks et al., US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 60, 1308 (May 1, 2015).
  4. L. N. Segal, M. J. Blaser, A brave new world: the lung microbiota in an era of change. Annals of the American Thoracic Society 11 Suppl 1, S21 (Jan, 2014).
  5. H. Ochman et al., Evolutionary relationships of wild hominids recapitulated by gut microbial communities. PLoS biology 8, e1000546 (Nov 16, 2010).
  6. A. H. Moeller et al., Cospeciation of gut microbiota with hominids. Science (New York, N.Y.) 353, 380 (Jul 22, 2016).
  7. R. E. Ley, C. A. Lozupone, M. Hamady, R. Knight, J. I. Gordon, Worlds within worlds: evolution of the vertebrate gut microbiota. Nature reviews. Microbiology 6, 776 (Oct, 2008).
  8. N. A. Bokulich et al., Antibiotics, birth mode, and diet shape microbiome maturation during early life. Science translational medicine 8, 343ra82 (Jun 15, 2016).
  9. J. K. Goodrich et al., Human genetics shape the gut microbiome. Cell 159, 789 (Nov 6, 2014).
  10. T. Yatsunenko et al., Human gut microbiome viewed across age and geography. Nature 486, 222 (May 09, 2012).
  11. M. Yassour et al., Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability. Science translational medicine 8, 343ra81 (Jun 15, 2016).
  12. T. Rees, M. Blaser, Waking up from antibiotic sleep. Perspectives in public health 136, 202 (Jul, 2016).
  13. M. J. Blaser, Who are we? Indigenous microbes and the ecology of human diseases. EMBO reports 7, 956 (Oct, 2006).
  14. M. J. Blaser, S. Falkow, What are the consequences of the disappearing human microbiota? Nature reviews. Microbiology 7, 887 (Dec, 2009).
  15. W. Visek, The Mode of Growth Promotion by Antibiotics. Journal of Animal Science 46, 1447 (1978).
  16. I. Cho et al., Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 488, 621 (Aug 30, 2012).
  17. L. M. Cox et al., Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 158, 705 (Aug 14, 2014).
  18. Y. R. Nobel et al., Metabolic and metagenomic outcomes from early-life pulsed antibiotic treatment. Nature communications 6, 7486 (Jun 30, 2015).
  19. D. Mahana et al., Antibiotic perturbation of the murine gut microbiome enhances the adiposity, insulin resistance, and liver disease associated with high-fat diet. Genome medicine 8, 48 (Apr 27, 2016).
  20. A. E. Livanos et al., Antibiotic-mediated gut microbiome perturbation accelerates development of type 1 diabetes in mice. Nature microbiology 1, 16140 (Aug 22, 2016).
  21. D. Y. Han, A. G. Fraser, P. Dryland, L. R. Ferguson, Environmental factors in the development of chronic inflammation: a case-control study on risk factors for Crohn’s disease within New Zealand. Mutation research 690, 116 (Aug 7, 2010).
  22. S. Y. Shaw, J. F. Blanchard, C. N. Bernstein, Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. The American journal of gastroenterology 105, 2687 (Dec, 2010).
  23. A. Hviid, H. Svanstrom, M. Frisch, Antibiotic use and inflammatory bowel diseases in childhood. Gut 60, 49 (Jan, 2011).
  24. C. Canova et al., Association of maternal education, early infections, and antibiotic use with celiac disease: a population-based birth cohort study in northeastern Italy. American journal of epidemiology 180, 76 (Jul 1, 2014).
  25. K. Marild, C. R. Kahrs, G. Tapia, L. C. Stene, K. Stordal, Infections and risk of celiac disease in childhood: a prospective nationwide cohort study. The American journal of gastroenterology 110, 1475 (Oct, 2015).
  26. L. Trasande et al., Infant antibiotic exposures and early-life body mass. International journal of obesity (2005) 37, 16 (Jan, 2013).
  27. A. Saari, L. J. Virta, U. Sankilampi, L. Dunkel, H. Saxen, Antibiotic exposure in infancy and risk of being overweight in the first 24 months of life. Pediatrics 135, 617 (Apr, 2015).
  28. T. A. Ajslev, C. S. Andersen, M. Gamborg, T. I. Sorensen, T. Jess, Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics. International journal of obesity (2005) 35, 522 (Apr, 2011).
  29. L. C. Bailey et al., Association of antibiotics in infancy with early childhood obesity. JAMA pediatrics 168, 1063 (Nov, 2014).
  30. R. Murphy et al., Antibiotic treatment during infancy and increased body mass index in boys: an international cross-sectional study. International journal of obesity (2005) 38, 1115 (Aug, 2014).
  31. C. A. Mbakwa et al., Early Life Antibiotic Exposure and Weight Development in Children. The Journal of pediatrics 176, 105 (Sep, 2016).
  32. B. S. Schwartz et al., Antibiotic use and childhood body mass index trajectory. International journal of obesity (2005) 40, 615 (Apr, 2016).
  33. F. I. Scott et al., Administration of Antibiotics to Children Before Age 2 Years Increases Risk for Childhood Obesity. Gastroenterology 151, 120 (Jul, 2016).
  34. J. C. Clemente et al., The microbiome of uncontacted Amerindians. Science advances 1, (Apr 03, 2015).
  35. M. J. Blaser, Antibiotic use and its consequences for the normal microbiome. Science (New York, N.Y.) 352, 544 (Apr 29, 2016).
  36. J. Metsala et al., Prenatal and post-natal exposure to antibiotics and risk of asthma in childhood. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 45, 137 (Jan, 2015).
  37. J. Metsala et al., Mother’s and offspring’s use of antibiotics and infant allergy to cow’s milk. Epidemiology (Cambridge, Mass.) 24, 303 (Mar, 2013).
  38. K. Korpela et al., Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. Nature communications 7, 10410 (Jan 26, 2016).
  39. N. T. Mueller et al., Prenatal exposure to antibiotics, cesarean section and risk of childhood obesity. International journal of obesity (2005) 39, 665 (Apr, 2015).
  40. M. B. Azad, S. L. Bridgman, A. B. Becker, A. L. Kozyrskyj, Infant antibiotic exposure and the development of childhood overweight and central adiposity. International journal of obesity (2005) 38, 1290 (Oct, 2014).
  41. J. Suez et al., Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature 514, 181 (Oct 09, 2014).
  42. B. Chassaing et al., Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 519, 92 (Mar 05, 2015).
  43. Y. Chen, M. J. Blaser, Helicobacter pylori colonization is inversely associated with childhood asthma. The Journal of infectious diseases 198, 553 (Aug 15, 2008).
  44. Y. Urita et al., Role of infected grandmothers in transmission of Helicobacter pylori to children in a Japanese rural town. Journal of paediatrics and child health 49, 394 (May, 2013).
  45. A. Gomez et al., Gut Microbiome of Coexisting BaAka Pygmies and Bantu Reflects Gradients of Traditional Subsistence Patterns. Cell reports 14, 2142 (Mar 08, 2016).
  46. M. J. Blaser, Helicobacter pylori and gastric diseases. BMJ (Clinical research ed.) 316, 1507 (May 16, 1998).
  47. M. Blaser. (Henry Holt and Co., New York, 2014), pp. 1-288.
  48. L. A. Hicks, T. H. Taylor, Jr., R. J. Hunkler, U.S. outpatient antibiotic prescribing, 2010. The New England journal of medicine 368, 1461 (Apr 11, 2013).
  49. J. S. Gerber et al., Variation in Antibiotic Prescribing Across a Pediatric Primary Care Network. Journal of the Pediatric Infectious Diseases Society 4, 297 (Dec, 2015).
  50. B. E. Jones et al., Variation in Outpatient Antibiotic Prescribing for Acute Respiratory Infections in the Veteran Population: A Cross-sectional Study. Annals of internal medicine 163, 73 (Jul 21, 2015).
  51. A. Ternhag, J. Hellman, More on U.S. outpatient antibiotic prescribing, 2010. The New England journal of medicine 369, 1175 (Sep 19, 2013).




Discover more from The Evolution and Medicine Review

Subscribe to get the latest posts sent to your email.

Discover more from The Evolution and Medicine Review

Subscribe now to keep reading and get access to the full archive.

Continue reading